Tadafumi Yokoyama

Tadafumi Yokoyama

Auto-generated profile, based on publicly available information

Tadafumi Yokoyama

Department of Pediatrics, Kanazawa University Hospital

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Clinical Immunology
Verified
Journal Article
Closed access
NSNaoto Sakumura
Naoto Sakumura
TYTadafumi Yokoyama
Tadafumi Yokoyama
MUMasaaki Usami
Masaaki Usami
YHYuiko Hosono
Yuiko Hosono
NINatsumi Inoue
Natsumi Inoue
TWTaizo Wada
Taizo Wada

19 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JRJorge Rodriguez-Gil
Jorge Rodriguez-Gil
DWDawn E. Watkins-Chow
Dawn E. Watkins-Chow
LBLaura Baxter
Laura Baxter
TYTadafumi Yokoyama
Tadafumi Yokoyama
PZPatricia M. Zerfas
Patricia M. Zerfas
WPWilliam J. Pavan
William J. Pavan
The rare lysosomal storage disorder Niemann-Pick disease type C1 (NPC1) arises from mutation of NPC1, which encodes a lysosomal transmembrane protein essential for normal transport and trafficking of cholesterol and sphingolipids. NPC1 is highly heterogeneous in both clinical phenotypes and age of onset. Previous studies have reported sub-Mendelian survival rates for mice homozygous for various Npc1 mutant alleles but have not studied the potential mechanisms underlying this phenotype. We performed the first developmental analysis of a Npc1 mouse model, Npc1em1Pav, and discovered significant fetal growth restriction in homozygous mutants beginning at E16.5. Npc1em1Pav/em1Pav mice also exhibited cyanosis, increased respiratory effort, and over 50% lethality at birth. Analysis of neonatal lung tissues revealed lipid accumulation, notable abnormalities in surfactant, and enlarged alveolar macrophages, suggesting that lung abnormalities may be associated with neonatal lethality in Npc1em1Pav/em1Pav mice. The phenotypic severity of the Npc1em1Pav model facilitated this first analysis of perinatal lethality and lung pathology in an NPC1 model organism, and this model may serve as a useful resource for developing treatments for respiratory complications seen in NPC1 patients.

1 March 2013 in Journal of Clinical Virology
Verified
Journal Article
Closed access
TYTadafumi Yokoyama
Tadafumi Yokoyama
YTYuko Tokuhisa
Yuko Tokuhisa
ATAkiko Toga
Akiko Toga
TFToshihiro Fujiki
Toshihiro Fujiki
YSYasuhisa Sakakibara
Yasuhisa Sakakibara
AYAkihiro Yachie
Akihiro Yachie

1 August 2011 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PDF file
TYT. Yokoyama
T. Yokoyama
NSN. Sugimoto
N. Sugimoto
KTK. Taniguchi
K. Taniguchi
SKS. Komoto
S. Komoto
TYT. Yuno
T. Yuno
AYA. Yachie
A. Yachie

9 October 2024 in American Journal of Nephrology
Verified
Journal Article
Closed access
TYTadafumi Yokoyama
Tadafumi Yokoyama
KOKevin J. O’bRien
Kevin J. O’bRien
TFTesiya M. Franklin
Tesiya M. Franklin
BZBen Long G. Zuo
Ben Long G. Zuo
MZMei Xing G. Zuo
Mei Xing G. Zuo
BGBernadette R. Gochuico
Bernadette R. Gochuico
Introduction: Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by defective biogenesis of lysosome-related organelles. The genetic types of HPS are associated with a spectrum of multisystemic clinical manifestations. Phenotypic features of HPS type 1 (HPS-1) or HPS-4, which are associated with defects in biogenesis of lysosome-related organelles complex-3 (BLOC-3), are generally more severe than those of HPS-3, HPS-5, or HPS-6, which are associated with defects in BLOC-2. A paucity of information is available about renal impairment in HPS. The objective of this study is to expand the understanding of kidney disease in HPS. Methods: Medical records and clinical data of patients with HPS evaluated at the National Institutes of Health Clinical Center from 1995 to 2020 were retrospectively reviewed. For patients with more than one visit, the most recent renal function and urinalysis tests were analyzed. Estimated glomerular filtration rate (eGFR) was calculated using standard equations (i.e., Chronic Kidney Disease Epidemiology Collaboration, Modification of Diet in Renal Disease). Kidney tissue sections from 5 patients with HPS-1 and 1 patient with HPS-6 were examined. Results: Records from 205 adults and 52 children with HPS were reviewed. Calculated eGFR of adult patients with different HPS types differed significantly, and calculated eGFR of pediatric and adult patients with BLOC-3 disorders was significantly lower than that of patients with BLOC-2 disorders. Linear regression analysis showed that renal function progressively decreases with age in patients with BLOC-3 or BLOC-2 disorders, but the rate of decline was more rapid in patients with BLOC-3 disorders compared to patients with BLOC-2 disorders. In adult patients with HPS-1, glucosuria was found in 4%, proteinuria in 12%, hematuria in 15%, high levels of urinary β2MG in 24%, and elevated urinary albumin to creatinine ratios in 9%. Histological examination of kidney tissue showed accumulation of intracellular deposits of ceroid lipofuscin in proximal renal tubular epithelial cells in patients with HPS-1. There was no evidence of fibrosis, and glomeruli, distal renal tubular epithelial cells, and interstitial regions appeared histologically normal. Conclusion: Mild impairment of renal function is a feature of HPS. Kidneys of patients with HPS-1 contain proximal renal tubular intracellular deposits and no histologic evidence of fibrosis. Consistent with other manifestations of HPS, the phenotype of renal impairment is relatively more pronounced in patients with BLOC-3 disorders than in patients with BLOC-2 disorders. Strategies to avoid nephrotoxicity or renal tubular injury and to protect renal function should be considered for patients with HPS irrespective of age.

11 February 2023 in Cureus
Verified
Journal Article
Open access
PDF file
TYTadafumi Yokoyama
Tadafumi Yokoyama
NSNaoto Sakumura
Naoto Sakumura
NINatsumi Inoue
Natsumi Inoue
YMYusuke Matsuda
Yusuke Matsuda
TWTaizo Wada
Taizo Wada
Immunoglobulin A vasculitis (IgAV) is the most common vasculitis of childhood. However, its etiology remains unknown. In the Mediterranean region, 10% of patients with IgAV harbor homozygous and compound heterozygous mutations in the Mediterranean fever (MEFV) gene. Thus, such mutations may be involved in the development of IgAV. Herein, we present a five-year-old girl presented with IgAV. She experienced prolonged abdominal pain, which was steroid-resistant. When treatment with colchicine was started, her abdominal pain resolved immediately. The serum interleukin (IL)-18 levels of the patient and other patients with IgAV and familial Mediterranean fever (FMF) were evaluated using enzyme-linked immunosorbent assay. The serum IL-18 level of the patient was higher than that of other patients with IgAV and was similar to that of patients with FMF harboring M694I mutation. Moreover, all exons of the MEFV gene were analyzed using the Sanger sequencing and the patient presented with E148Q/M694I mutation. Further, a comprehensive search of Japanese patients with IgAV harboring MEFV gene mutations in PubMed, Ichushi-Web, and Medical Online was conducted to validate the clinical characteristics of Japanese patients with IgAV harboring MEFV gene mutation. In previous studies, only five patients presented with IgAV harboring MEFV gene mutation in Japan. The prevalence of IgAV associated with MEFV gene mutation may be low in Japan. However, MEFV gene mutations should be suspected if the symptoms of IgAV are prolonged or if patients are refractory to treatment. In such case, IL-18 monitoring and colchicine treatment may be useful for IgAV with MEFV gene mutation.